throbber
1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 1
`
` THE UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`COALITION FOR AFFORDABLE DRUGS VIII LLC
`Petitioner
`v.
` THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
`Patent Owner
`_____________________
`Case IPR2015-01836
`U.S. Pat. No. 7,932,268
`Case IPR2015-01835
`U.S. Pat. No. 8,618,135 B2
`________________________
`
`Deposition of Daniel J. Rader, MD
`Philadelphia, PA
`Tuesday, August 23, 2016
`
`Reported by: Jennifer Billstein-Miller
`Job No: 111717
`
`TSG Reporting - Worldwide 877-702-9580
`
`CFAD Exhibit 1055
`
`

`
`Page 2
`
`A P P E A R A N C E S:
`MCNEELY HARE & WAR
`CHRISTOPHER CASIERI, ESQUIRE
`12 Roszel Road
`Princeton, NJ 08540
`Counsel for Petitioner
`
`GOODWIN PROCTER
`WILLIAM JAMES, ESQUIRE
`901 New York Avenue, N.W.
`Washington, D.C. 20001
`Counsel for Patent Owner
`
`1 2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 3
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` - - -
` P R O C E E D I N G S
` - - -
` DANIEL J. RADER, M.D., after
` having been first duly sworn, was
` examined and testified as follows:
` - - -
` E X A M I N A T I O N
` - - -
`BY MR. CASIERI:
` Q. Good morning, Dr. Rader.
` A. Good morning.
` Q. Have you ever had your deposition
`taken before?
` A. No.
` Q. Okay. Just in case your attorney
`here didn't go through the basics, which I'm
`sure he did, I'm going to ask questions, you'll
`give the answers and the Court Reporter will
`take down the answers.
` A. Uh-hum.
` Q. The Court Reporter can't really see
`you shaking your head yes or shaking your head
`no, so it's hard, but if you can try to
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 4
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`remember to verbalize your answers.
` A. Sure.
` Q. And I have trouble hearing yeahs and
`nos, so if you can try to articulate those two.
` A. Sure.
` Q. And then if you need a break at any
`time, just let me know, and you can have a
`break.
` A. Okay.
` Q. And I'll try to make my questions as
`clear as possible, but if you don't understand
`a question, let me know; otherwise, I'm going
`to assume that you do understand the question.
` A. Okay.
` Q. That's pretty much it.
` So let's get started here. I'm
`going to hand you what's been marked Penn
`Exhibit 2026. It's titled Declaration of
`Daniel Rader.
` Just take a quick look at that.
`And I'm just going to ask you to turn to the
`back page. And if you would, confer for me
`that your signature?
` A. It is.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 5
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` Q. Okay. So what we're just going to do
`is go through this, probably not every
`paragraph, but I'll just start off by just
`pointing you to a paragraph and I'll ask you
`some questions about it.
` A. Sure.
` Q. So why don't you turn to paragraph
`number two on page two.
` A. Yes.
` Q. Okay. You indicate here that, I'm a
`medical doctor with over 25 years of experience
`treating patients with a focus on treating
`patients suffering from lipid disorders.
` A. Uh-hum.
` Q. Do you see that?
` A. Yes.
` Q. When did you start treating patients?
` A. I graduated from medical school in
`'84, did a residency in internal medicine, and
`I completed in '88, and then I did further
`training in lipid disorders starting in '88.
` Q. And do you still treat patients today
`for lipid disorders?
` A. I do.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 6
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` Q. In the interim between now and 1988,
`were you always treating patients for lipid
`disorders?
` A. Yes.
` Q. Are you a cardiologist?
` A. No, I'm an internist.
` Q. Let's turn to paragraph 12. Today,
`I'm going to jump into the middle of a lot of
`these paragraphs.
` A. Sure.
` Q. But you're free to read the entire
`paragraph if you want. If you need to take a
`minute to read it, just let me know, and you
`can have that; otherwise, I'll just jump in
`where I need to.
` In paragraph 12, right in the
`middle there -- actually, let's start at the
`end -- you indicate, in my practice, I
`regularly treat patients with
`hypercholesterolemia with these types of drugs
`in addition to a suggested regiment of low fat
`diet and regular exercise; do you see that?
` A. Yes.
` Q. And these types of drugs, you're
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 7
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`talking about statins and fibrates?
` A. And ezetimibe, the ones that are
`listed above.
` Q. Is ezetimibe a different class of
`drugs?
` A. Different class, yes.
` Q. Do you know when you started to treat
`patients with statins?
` A. Statins, if memory serves, came out
`in I believe 1988, so started using them
`shortly thereafter.
` Q. And fibrates, how long have you been
`treating patients with fibrates?
` A. Fibrates are relatively old drugs, so
`I would also say since, you know, I started
`treating with patients with lipid disorders,
`'88 or so.
` Q. How about ezetimibe?
` A. Again, ezetimibe came to the market
`roughly a decade or a little more than a decade
`ago, so I don't know the exact year, but it
`would have been mid -- mid-2000.
` Q. Is there any other drug that you
`would regularly treat patients with
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`hypercholesterolemia?
` A. I use a class of medicines not listed
`here called bile acid sequestrants.
` Q. What are those?
` A. What are the names of the drugs?
` Q. Yeah, can you just repeat it for me.
` A. Bile acid sequestrants.
` Q. Any other drugs that you regularly
`treat patients with hypercholesterolemia?
` A. In the past, I've used niacin, but we
`don't use niacin much any more.
` Q. Would you say you can satisfactorily
`treat patients with hypercholesterolemia with
`one or more of these drugs?
` MR. JAMES: Objection to the
` form.
` You can answer the question if
` you understand it.
` THE WITNESS: Can you repeat the
` question? I just want to make sure I
` understand it.
`BY MR. CASIERI:
` Q. Yeah. Can you say you can
`satisfactorily treat patients with
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 9
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`hypercholesterolemia with one or more of these
`drugs?
` MR. JAMES: Same objection.
` THE WITNESS: It's a pretty
` generic question. There are many patients
` who can't be treated satisfactorily with
` these -- with these drugs.
`BY MR. CASIERI:
` Q. Why not?
` A. They have a high level of cholesterol
`that can't be successfully treated with the --
`with the existing medications or they don't
`tolerate the existing medications.
` Q. And what do you do for those
`patients?
` A. Now or historically or what, give me
`a time frame?
` Q. Okay. Well, let's start with now,
`what do you do with those patients now?
` A. There's a new class of drugs that got
`approved a year ago called the PCSK9
`inhibitors. So that's one option, new option
`for such patients. Patients with HoFH
`specifically, very specific condition, can be
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 10
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`treated with lomitapide or mipomersen, two
`approve drugs for that condition.
` Q. You mentioned HoFH. Just so we're
`clear, we're talking about the same thing,
`that's an acronym?
` A. That's an acronym for homozygous
`familial hypercholesterolemia.
` Q. And so you'll understand if I say
`HoFH that we're talking about?
` A. I will.
` Q. Okay. Can you treat patients with
`HoFH with PCSK9 inhibitors?
` A. You can try. In general, they're not
`all that effective, although in the subset of
`patients, they may have some effect.
` Q. Now, earlier, when you said there
`were, I guess, a class of patients who had a
`high level of cholesterol or don't tolerate the
`drugs, the statins or the sequestrants, were
`you specifically talking about patients with
`HoFH, or were you talking about more than just
`patients with HoFH?
` A. No, that wasn't specific to HoFH.
` Q. So would it be fair to say some
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 11
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`patients with, I guess, standard high
`cholesterol just can't tolerate some statins?
` A. I mean, we don't use "standard high
`cholesterol" as a medical term.
` Q. Okay.
` A. But it's fair to say that there are
`patients who can't tolerate statins, yes.
` Q. I'm going to jump ahead to paragraph
`23. I'm going to hand you what's been marked
`Penn Exhibit 2078.
` Do you recognize this document?
` A. I do.
` Q. Okay. In the first sentence of
`paragraph 23 of your declaration, you indicated
`it was discovered in these CV145-002 clinical
`studies that lomitapide causes severe
`gastrointestinal side effects; do you see that?
` A. Yes.
` Q. This document that I just handed you,
`Exhibit 2078, is related to the trial clinical
`study CV145-002.
` A. Yes, I believe so.
` Q. Were you involved at all in
`CV145-002?
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 12
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` A. No.
` Q. So now, in your declaration, you
`reference Exhibit 2078 as being a true and
`accurate copy of the BMS-201,038 Investigative
`Brochure General Addendum.
` A. Uh-hum.
` Q. When did you become aware of the
`clinical studies CV145-002?
` MR. JAMES: Dr. Rader, you
` should take whatever time you need to look
` at your declaration in order to answer any
` of these questions.
` THE WITNESS: Okay. Maybe I'll
` read over paragraph 23.
` I don't remember specifically
` when I became aware of that study.
`BY MR. CASIERI:
` Q. Well, did you become aware of it at
`or around the time that you were preparing this
`declaration or sometime prior to when you were
`preparing the declaration?
` A. I became aware of these results prior
`to the preparation of the declaration.
` Q. Do you know about when you might have
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`become aware of the results of the studies of
`CV145-002?
` A. It's difficult to give a specific
`date or year. I was aware of these results
`prior to the design of our phase 2 trial in
`HoFH patients. That puts it at least at a
`certain point in time.
` Q. Your phase 2 trial in the HoFH
`patients, do you remember about what time or
`what date that took place?
` A. I have to refresh my memory by
`looking at the declaration.
` Q. Sure.
` A. So I'm going to read from paragraph
`36. By at least December 2nd, 2002, I had
`developed a clinical protocol for a phase 1/2
`open-labeled, dose-escalation study in patients
`with HoFH.
` Paragraph 42, on March 30th,
`2003, I received a communication from the IRB
`noting that it was approved.
` Paragraph 43, the first patient
`received the first dose during the week of
`June 30th, 2003, and the study was complete on
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 14
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`January 18, 2004.
` Q. Okay. Just so I'm clear, you were
`aware of the results of the clinical studies of
`CV145-002 prior to developing the clinical
`protocol for your tests of HoFH patients?
` A. Correct.
` Q. Okay. Let's get these out, I guess.
`I'm going to hand you what's been marked as
`Exhibit 2077.
` Is that the clinical protocol
`for the trial that you just mentioned with
`regard to paragraph 36?
` A. Yes, it is.
` Q. Okay. So let's take a look back at
`paragraph 23 for a minute.
` The information that you have in
`paragraph 23, and I won't read it all into the
`record, but that information, did that come
`from your memory, or did it come from you
`reviewing Docket Exhibit 2078?
` A. I don't recall.
` Q. As you're sitting here today, do you
`know if all the information in this paragraph
`is accurate?
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` A. Well, I could certainly take the time
`to look at this paragraph and compare it to
`what other data we have.
` Q. When you say you don't recall, did
`you prepare this declaration?
` A. I did, I had substantial input into
`the preparation and editing of this document,
`yes.
` Q. Do you have any reason to believe
`that the information contained in paragraph 23
`is inaccurate?
` A. I have no reason to believe that it
`would be inaccurate, no.
` Q. Okay. Could you open it up to, open
`up the Exhibit 2078 to page 204.
` A. Yup.
` Q. In the middle there of the middle
`paragraph, the first sentence indicates, in
`this protocol, 36 hypercholesterolemic healthy
`volunteers were recruited in four groups of
`nine subjects each to receive in an ascending
`fashion doses of BMS-201,038 of 10, 25, 50 or a
`hundred milligrams were matched placebo
`capsules QD for 14 days; do you see that?
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 16
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` A. Yes.
` Q. Do you know what they mean by
`ascending fashion doses?
` A. That's a term in drug development in
`which different groups of patients are given
`doses of the drug in an ascending fashion;
`meaning, one group gets one dose, the next dose
`gets a higher dose, the next group gets a
`higher dose.
` Q. So no subjects are receiving 10, then
`25, 50?
` A. No.
` Q. They're receiving one dose and only
`one dose?
` A. Correct.
` Q. You say in your declaration, still in
`paragraph 23, about time and dose related
`decrease in LDL cholesterol was observed all
`doses cause gastrointestinal side effects with
`more frequent and severe gastrointestinal side
`effects at higher doses, so that includes the
`10-milligram dose; do you know?
` MR. JAMES: Objection to the
` form.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` THE WITNESS: The abbreviated
` clinical study report, it doesn't
` specifically touch on the 10 milligram.
`BY MR. CASIERI:
` Q. Okay. Is it fair to say that what
`you know about the results of CV145-002 is
`contained in what's in this report, which is
`Penn Exhibit 2078?
` MR. CASIERI: Objection to the
` form.
` THE WITNESS: At one point I was
` shown data related to this trial that was
` more extensive than what is included in
` this abbreviated study report.
`BY MR. CASIERI:
` Q. And do you remember the data
`concerning the 10 milligram group of patients?
` A. I don't specifically remember.
` Q. Is the 10-milligram dose therapeutic
`or subtherapeutic dose?
` A. Define "therapeutic"?
` Q. Why don't we -- I'll strike that
`question for now.
` Why don't we turn to paragraph
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 18
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`40 of your declaration. Right in the middle,
`second sentence, actually, you say instead, we
`were evaluating a forced titration regimen that
`required patients to receive an initial very
`low subtherapeutic dose, followed by at least
`three substantially increased doses of
`lomitapide to confirm that this forced dose
`titration would reduce side effects.
` So my question to you is, what
`do you mean there by subtherapeutic dose?
` A. This was a trial in HoFH patients.
`What I mean there is that we expected that that
`dose would have minimal effect in reducing LDL
`cholesterol in these HoFH patients.
` Q. Okay. So, with that definition in
`mind, is the 10-milligram dose a subtherapeutic
`dose?
` MR. JAMES: Objection to form.
` Vague and ambiguous.
` THE WITNESS: I think the answer
` to that question depends on what type of
` patient is being treated.
`BY MR. CASIERI:
` Q. Okay. So, for a 10-milligram dose of
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 19
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`lomitapide, it could be a therapeutic dose or a
`subtherapeutic dose depending on the patient?
` A. Yes.
` Q. Do you know what kind of diet the
`volunteers in CV145-002 were following during
`the trial?
` A. So, reading from the study report,
`all subjects entered for a seven-day dietary
`lead in with an AHA step-one diet, which was
`maintained throughout the study. I can't
`define that specifically for you, but I know
`it's a low fat diet.
` Q. You don't know any other details
`about the AHA step-one diet other than --
` A. Other than the fact that it's a low
`fat diet, no.
` Q. If you wanted to find out about the
`specifics of that diet, what would you do, in
`the specifics of that diet and the time frame
`of this study?
` A. I'm not sure I understand your
`question.
` Q. I'm just trying to figure out -- I'm
`sorry, it's not a trick question or anything.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 20
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`I'm just trying to figure out how one would go
`about determining what this AHA step-one diet
`is.
` A. AHA stands for the American Heart
`Association. So I suppose going to the source
`would be -- you have to do that.
` Q. Okay. Do you know if the -- still on
`this Exhibit 2078, do you know if the patients
`on the 10-milligram dose acclimated to the
`drug?
` A. I don't know.
` Q. On page three of four, right in the
`middle of the paragraph there, it says the
`spectroscopic results indicate that in
`comparison with baseline and with placebo,
`there appear to be some increase in hepatic fat
`content at all doses.
` Do you know if there was any
`uncertainty as to whether there was actually
`hepatic fat content in all doses?
` A. Do I know if there was any
`uncertainty, I want --
` Q. Yeah.
` A. Can you repeat the question?
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 21
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` Q. Yeah.
` A. I want to understand what you're
`asking.
` Q. I'm focusing on the term "there
`appear to be" in that sentence. I'm just
`trying to understand, if you know, do you know
`for sure there was increase in hepatic fat
`content in all doses, or was there some
`uncertainty?
` A. I don't know. We have the data that
`are here.
` Q. Well, let's move onto paragraph 24.
`In the very first sentence, you say, due to my
`prior relationship with Dr. Gregg and
`Dr. Wetterau, I became involved in clinical
`testing conducted by BMS on lomitapide; do you
`see that?
` A. Yes.
` Q. What clinical testing are you
`referring to -- strike that.
` What involvement did you have in
`the clinical testing conducted by BMS of
`lomitapide?
` A. I go on to describe in that statement
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 22
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`in more detail through my involvement in
`CV145-009. Just reading from the declaration,
`I was one of the clinical trial investigators
`for CV145-009.
` Q. And I'll show you what's been marked
`Penn Exhibit 2080.
` Is this is the clinical trial
`you're referring to paragraph 24 of your
`declaration?
` A. Yes.
` Q. So what is this document?
` A. Well, it's stated on the cover sheet
`an abbreviated clinical study report.
` Q. And was Dr. Gregg and Dr. Wetterau
`working at BMS at the time that you were
`involved in this clinical study?
` A. Yes, to the best of my knowledge,
`yes, uh-hum.
` Q. And where were you working at the
`time?
` A. I was at University of Pennsylvania.
` Q. You were at a study site at this
`clinical trial?
` A. I was.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 23
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` Q. How much interaction did you have
`with Dr. Gregg and Dr. Wetterau?
` A. Specific to this clinical trial?
` Q. Yeah.
` A. Dr. Wetterau, none. Dr. Gregg,
`essentially, none as well. He had no direct
`role in running this trial for BMS, if my
`memory serves.
` Q. You had worked with either Dr. Gregg
`or Dr. Wetterau prior to that?
` A. I had worked with Dr. Gregg when we
`were both at the NIH, where he left to join
`BMS.
` I mostly knew Dr. Wetterau
`through scientific meetings.
` Q. Did anyone at BMS ever mention
`concerns about lomitapide causing
`phospholipidosis?
` MR. JAMES: Objection to the
` form. Vague as to time.
` THE WITNESS: Could you clarify
` when that might have been?
`BY MR. CASIERI:
` Q. Yes, at any time prior to 2005.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 24
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` A. Yes.
` Q. Who mentioned concern about
`phospholipidosis?
` A. I don't remember.
` Q. Do you remember anything about the
`conversation with the person who mentioned a
`concern about phospholipidosis?
` A. I don't have a specific memory of a
`conversation. But I do have a memory of the
`fact that it was a concern, which was the
`reason we included pulmonary function tests and
`spirometry in this clinical protocol.
` Q. And do you know what the results of
`the pulmonary function test and spirometry
`were?
` MR. JAMES: Objection. Which
` clinical trial are you referring to in
` that question?
` THE WITNESS: Should I assume
` that you're referring to the '09 trial
` that we've been discussing that we have in
` front of us?
` MR. CASIERI: Yes. Counsel,
` you're supposed to object to the form.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 25
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` You know, we're not having a conversation.
` MR. JAMES: Ask a clear question
` and I won't object.
` MR. CASIERI: No, just object to
` the form. If I don't think it's clear,
` I'll reword it.
` MR. JAMES: I'm making the
` objections which I think are appropriate.
` MR. CASIERI: That's not an
` objection. You asking me about my
` question is not an objection.
` MR. JAMES: It is an objection.
` MR. CASIERI: No, it isn't.
` MR. JAMES: Just ask questions.
` THE WITNESS: So I'm looking at
` the clinical study report to see if
` there's any mention specifically of the
` pulmonary function test and spirometry. I
` don't see any mention in this report of
` those safety testing results.
`BY MR. CASIERI:
` Q. Do you have any recollection yourself
`of the results of those safety testing at your
`own study center?
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 26
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` A. No, I don't.
` Q. So my next question is, did anyone at
`BMS ever mention any concerns about lomitapide
`causing hERG inhibition prior to 2005?
` A. I don't have a specific memory of
`that having been mentioned.
` Q. Are there any particular tests in the
`protocol that would lead you to believe that
`that was a concern?
` MR. JAMES: Objection. Vague.
` THE WITNESS: And you're talking
` about the '09 protocol, correct?
`BY MR. CASIERI:
` Q. Correct.
` A. I don't see a specific description of
`it. But a study like this would be expected to
`have included in ECG or multiple ECGs, but I
`don't see it specifically mentioned in this
`study report.
` Q. An ECG test would uncover hERG
`inhibition; is that fair to say?
` A. It's not a specific test for hERG
`inhibition, but it's a test for QT
`prolongation.
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 27
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` Q. If you would turn to page two of
`Exhibit 2080. Towards the bottom, there's a
`section starting with methodology; do you see
`that?
` A. Yup.
` Q. And the very first center, actually,
`second sentence, after adherence to a low fat,
`low cholesterol diet conforming to the National
`Cholesterol Education Program step-one diet for
`at least two weeks; do you see that?
` A. I do.
` Q. Is that the same diet that we were
`discussing before with regard to your earlier
`clinical trial CV145-002?
` A. Well, what it says here is NCEP
`step-one diet. The other one said AHA step-one
`diet. And, frankly, I don't -- I don't know
`the --
` Q. The first sentence, it says, after
`adherence to a low fat, low cholesterol diet
`for at least two weeks and no treatment with
`lipid-lowering agents for a minimum of four
`weeks, subjects entered into a four-week,
`single-blind placebo lead-in period, period A;
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 28
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`do you see that?
` A. Uh-hum.
` Q. Do you know if they were on a special
`diet during the testing phase?
` A. Define "testing phase," just so I
`understand?
` Q. Do you know if they were --
` A. Taking the placebo or taking the
`lomitapide?
` Q. Taking the lomitapide.
` A. Yes, the answer is, yes, the -- the
`idea is to put them on the low fat diet and
`leave them on that diet throughout the course
`of that study.
` Q. What is a four-week, single-blind
`placebo lead-in period?
` A. I believe what that refers to in this
`context of this trial is that all the study
`subjects were placed on a placebo for four
`weeks where they didn't know they were
`receiving placebo, but the investigators did,
`hence the term single blind.
` Q. So when did they receive the drug?
` A. Let me just refresh my memory here on
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 29
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`the methodology.
` After successful completion of
`dietary and placebo lead-in, subjects were
`randomized in a one-to-one ratio to receive
`once daily doses of BMS-201,038 for matched
`placebo. So, essentially, at the end of the
`four-week, single-blind placebo period they
`were randomized to either lomitapide or
`placebo.
` Q. Just so I am clear, do you know any
`specifics of the NCEP step-one diet?
` A. I don't, no.
` Q. And the subjects in CV145-009, did
`they have HoFH?
` A. No.
` Q. Did they have hypercholesterolemia?
` A. They had an LDL cholesterol greater
`than 160 milligram per deciliter, which would
`be conventionally considered to be
`hypercholesterolemia.
` Q. Okay. Let's take a look at 30,
`paragraph 30, of your declaration. I'm just
`going to read the first sentence there:
`Despite the major GI side effects -- GI is
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 30
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`gastrointestinal side effects?
` A. Yes.
` Q. -- an increase in hepatic fat with
`lomitapide seen in study CV145-009. I believe
`the dramatic clinical efficacy in LDL-C
`reduction of lomitapide may have viable
`molecule for potential further development for
`use in patients with HoFH where the unmet
`medical need was substantial.
` Did I get that right?
` A. Yes.
` Q. What was it that made you -- strike
`that.
` After your experience with
`CV145-009, did you believe that there was
`potential to treat non-HoFH patients with
`lomitapide?
` A. Lomitapide reduced LDL cholesterol
`substantially in that -- in that study which
`was in as we discussed non-HoFH patients, but
`it also had major side effects and toxicities,
`making its further clinical development in the
`non-HoFH setting extremely challenging.
` Q. So what was it about the HoFH
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 31
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
`patients that made you think lomitapide would
`be a viable molecule for potential further
`development?
` A. HoFH is a very severe form of
`hypercholesterolemia. As I state here, the
`unmet medical need at the time was substantial
`and the risk of heart attack, stroke and death
`was very high, so I felt that it may be a
`condition where lomitapide might be acceptable
`despite its side effects and toxicities.
` Q. And at that time, did you consider
`any other MTP inhibitors for potential further
`development for use in patients with HoFH?
` A. I don't recall.
` Q. So, in paragraph 31, you indicate
`that after the termination of lomitapide
`development by BMS, I approached BMS with the
`idea of donating the molecule to Penn so that
`we could test it in patients with HoFH for
`which there were no efficacious cholesterol
`treatments; do you see that?
` A. Yes.
` Q. Did you specifically tell BMS that
`you only wanted to test it on HoFH patients?
`
`TSG Reporting - Worldwide 877-702-9580
`
`

`
`Page 32
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` DANIEL J. RADER, M.D.
` A. I don't specifically recall my
`initial communication, but I was clear that the
`first study I wanted to do, if they were
`willing to transfer the molecule, was in
`patients with HoFH.
` Q. Do you know if BMS was trying to
`treat any patients with HoFH, trying to develop
`a drug to treat patients with HoFH?
` A. At what time period?
` Q. When you approached them about
`donating the molecule to Penn.
` A. Are you asking if they were trying to
`treat HoFH with lomitapide or with any drug?
` Q. With any drug.
` A. With regard to lomitapide, I don't
`believe they had any plans to treat HoFH. With
`regard to another drug, I really don't know.
` Q. Now, at the time you approached BMS,
`were an at all

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket